When to Order Imaging for Staging and Post-Therapy Assessment of Head and Neck Cancer: ACR Appropriateness Decoded

A patient presents with a new, firm cervical lymph node and a history of smoking. Another has completed chemoradiation for oropharyngeal cancer and now reports vague throat pain. In both scenarios, accurate imaging is critical for determining the next steps, but the optimal study—contrast-enhanced CT, MRI, or FDG-PET/CT—is not always obvious. Choosing incorrectly can delay diagnosis or miss recurrent disease. This guide decodes the American College of Radiology (ACR) Appropriateness Criteria to help you select the right imaging test for staging and post-therapy assessment of head and neck cancer, ensuring timely and effective patient care.

What Does ACR Staging and Post-Therapy Assessment of Head and Neck Cancer Cover?

These ACR guidelines, updated by the Neurologic panel on May 11, 2026, provide evidence-based recommendations for imaging patients with suspected or diagnosed squamous cell carcinoma and other malignancies of the head and neck. The criteria cover the most common primary sites, including the oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, paranasal sinuses, nasal cavity, and major salivary glands. They also address the workup of a neck mass concerning for metastasis from an unknown primary site. These recommendations apply to both initial staging at the time of diagnosis and post-treatment surveillance or evaluation for suspected recurrence. This document does not cover imaging for thyroid cancer, cutaneous malignancies of the head and neck, or non-malignant processes, which are addressed in separate ACR guidelines.

What Imaging Should I Order for Staging and Post-Therapy Assessment of Head and Neck Cancer? Recommendations by Clinical Scenario

The choice of imaging for head and neck cancer depends heavily on the primary tumor location and whether the goal is initial staging or post-treatment assessment. The ACR provides specific guidance for each context.

For the initial staging of suspected cancer of the oral cavity, oropharynx, hypopharynx, larynx, or an unknown primary, the ACR rates several modalities as Usually Appropriate. These include MRI of the orbits, face, and neck without and with IV contrast, which offers superior soft-tissue contrast for delineating tumor extent, and CT of the neck with IV contrast, which is excellent for evaluating bone invasion and cervical lymph nodes. FDG-PET/CT from the skull base to mid-thigh is also Usually Appropriate for detecting nodal and distant metastatic disease, which is crucial for comprehensive staging.

When the suspected malignancy is in the nasopharynx or is an EBV-associated unknown primary, the same core studies (MRI, CT neck, PET/CT) are Usually Appropriate. However, FDG-PET/MRI from the skull base to mid-thigh also receives a Usually Appropriate rating, reflecting its value in combining the high soft-tissue resolution of MRI with the metabolic data of PET, particularly for assessing skull base invasion.

For initial staging of cancers in the paranasal sinuses, nasal cavity, or a major salivary gland (parotid, submandibular, sublingual), the recommendations are consistent: MRI without and with contrast, CT neck with contrast, and FDG-PET/CT are all considered Usually Appropriate. MRI is particularly valuable for assessing perineural spread, a common concern with salivary gland malignancies.

In the post-treatment setting—for surveillance or suspected recurrence—the imaging recommendations largely mirror those for initial staging across all subsites (oral cavity/oropharynx, nasopharynx, sinuses, salivary glands). MRI without and with contrast, CT neck with contrast, and FDG-PET/CT remain Usually Appropriate. Differentiating post-treatment changes like fibrosis and inflammation from recurrent tumor can be challenging, and a combination of anatomic (CT/MRI) and metabolic (PET) imaging is often required for an accurate assessment.

ACR Imaging Recommendations Table

Adult vs. Pediatric Staging and Post-Therapy Assessment of Head and Neck Cancer Imaging: Radiation Dose Tradeoffs

While head and neck cancers are far more common in adults, they can occur in children and adolescents. The ACR guidelines for this topic provide pediatric-specific Relative Radiation Levels (RRLs), reflecting the critical importance of the As Low As Reasonably Achievable (ALARA) principle in younger patients. Children have a longer life expectancy, which increases the lifetime risk of potential stochastic effects from ionizing radiation. For this reason, non-ionizing modalities like MRI (RRL of 0 mSv) and ultrasound are often preferred when clinically appropriate. When CT or PET/CT is necessary, pediatric protocols must be optimized to use the lowest possible radiation dose that still achieves diagnostic image quality. For example, a pediatric neck CT has an RRL of 0.3-3 mSv, significantly lower than the adult equivalent of 1-10 mSv. Clinicians must weigh the diagnostic benefits of each study against the cumulative radiation exposure, particularly in children who may require multiple surveillance scans over their lifetime.

Imaging Protocol Details for Staging and Post-Therapy Assessment of Head and Neck Cancer

Once you’ve decided on the right study, the specific imaging protocol is essential for obtaining diagnostic-quality images. Key considerations include the field of view, slice thickness, and the timing and administration of intravenous contrast. Our protocol guides provide detailed, scannable instructions for the studies recommended above. While vascular imaging is not a primary staging tool, understanding its protocol is useful when specific questions of vessel encasement arise. You can find detailed guides in our library, such as:

• MRA Neck With and Without Contrast

Tools to Help You Order the Right Study

Selecting the optimal imaging study from a long list of possibilities can be challenging. GigHz offers several tools designed to streamline this process, ensuring your order is evidence-based and appropriate for the clinical question.

The Imaging Appropriateness Selector provides a searchable interface to the complete ACR guidelines, allowing you to quickly find recommendations for clinical scenarios beyond the staging and post-therapy assessment of head and neck cancer.

For detailed procedural information, the Imaging Protocol Library offers step-by-step guides for hundreds of imaging studies, helping you understand the technical details behind the recommendations.

To help manage and communicate radiation exposure with your patients, the Radiation Dose Calculator can estimate cumulative effective dose from various imaging studies, supporting informed clinical decision-making and patient counseling.

Frequently Asked Questions

Why is FDG-PET/CT so frequently rated ‘Usually Appropriate’ for head and neck cancer?

FDG-PET/CT is a powerful hybrid imaging modality that combines functional (metabolic) information from PET with anatomic detail from CT. For head and neck cancer, it is exceptionally sensitive for detecting occult primary tumors (in cases of cancer of unknown primary), identifying nodal metastases that may be normal in size on CT or MRI, and finding distant metastatic disease (e.g., in the lungs or bones). This whole-body assessment in a single scan is critical for accurate staging, which directly impacts treatment planning.

When is MRI preferred over CT for head and neck cancer?

MRI is generally preferred over CT when superior soft-tissue contrast is needed to answer a specific clinical question. This includes assessing the extent of a primary tumor in areas like the tongue base or tonsil, evaluating for perineural tumor spread (a key concern in salivary gland and sinonasal cancers), and assessing for skull base or intracranial invasion. In the post-treatment neck, MRI can sometimes be better at differentiating scar tissue from recurrent tumor, although this remains a significant diagnostic challenge for all modalities.

How long after radiation therapy should a surveillance PET/CT be performed?

It is generally recommended to wait at least 12 weeks (3 months) after the completion of radiation therapy before performing a surveillance FDG-PET/CT. Radiation induces intense inflammation in the treated tissues, which is metabolically active and will appear “hot” on a PET scan. Performing the scan too early can lead to a false-positive result, causing unnecessary patient anxiety and potentially leading to invasive biopsies of benign post-treatment changes. The 12-week waiting period allows this post-radiation inflammation to subside, increasing the specificity of the PET/CT for detecting true residual or recurrent disease.

Is a dedicated chest CT necessary if a staging PET/CT is performed?

In most cases, a dedicated diagnostic-quality chest CT is not necessary if a staging FDG-PET/CT has been performed. The CT component of a modern PET/CT scanner provides sufficient anatomic detail of the lungs to detect most significant metastatic nodules. A dedicated chest CT with IV contrast might be considered if there is a specific question about mediastinal or hilar lymph node involvement or vascular invasion that is not clearly answered by the PET/CT, but for routine screening for pulmonary metastases, the PET/CT is typically sufficient.

Why is ultrasound only ‘May be appropriate’ for staging and surveillance?

Ultrasound is an excellent tool for evaluating superficial structures in the neck, particularly cervical lymph nodes and the salivary and thyroid glands. It can be used to guide fine-needle aspiration (FNA) of suspicious nodes. However, it is limited in its ability to visualize deep structures of the head and neck, such as the primary tumor in the pharynx or larynx, or to assess for bone invasion. Therefore, while it serves as a valuable adjunct for targeted evaluation and biopsy, it is not sufficient as a standalone modality for comprehensive cancer staging or surveillance, which requires the broader anatomic coverage provided by CT, MRI, or PET/CT.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026